UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely CRISPR Therapeutics is implementing good security practices.
Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and colleagues at University of California. The company has partnerships with Novartis and Regeneron.
This report shows a preliminary security rating for CRISPR Therapeutics. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.Get a deeper scan →
Read more about the latest issues in cybersecurity
Role-based access control (RBAC), also known as role-based security, is an access control method ...
Cyber risk is defined as exposure to harm or loss resulting from data breaches or cyber attacks on ...
Compare CRISPR Therapeutics's security performance with other companies